Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
Biopharmaceutical Report I Issue18_December 2018 Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study...
Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake
Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval
Shooting for the Universe
Biosimilar Uptake Still Plagued by Interchangeability Hurdles
Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments
BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica
Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations
Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery
Medical Device: Growing Cybersecurity Threat and Need for More Regulation